Shareholder alert: robbins llp informs investors of class action against spero therapeutics, inc. (spro)

San diego--(business wire)---- $spro #fda--spero therapeutics, inc. (spro) failed to obtain fda approval of one of its lead product candidates

SPRO Ratings Summary

SPRO Quant Ranking